Bacterial and fungal co-infection is a major barrier in COVID-19 patients: A specific management and therapeutic strategy is required

Sahu, Tarun; Verma, Henu Kumar; Bhaskar, L. V. K. S.

doi:10.5501/wjv.v11.i2.107

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…stercoralis infection in patients with COVID‐19, particularly those with severe disease receiving immunosuppressive drugs. Numerous studies have reviewed the relationship between COVID‐19 and viral, fungal and bacterial co‐infection(s) 51–53 . However, there has been a lack of systematic reviews on parasite–COVID‐19 co‐infections.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Strongyloides coinfection in COVID‐19 patients treated with corticosteroids: A systematic review

Zulfiqar

Gasser

Ghodsian

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

The COVID‐19 pandemic linked to the virus SARS‐CoV‐2, which began in China, affected ∼765 million people as of 30 April 2023. The widespread use of corticosteroids for the symptomatic treatment of COVID‐19 could lead to the reactivation of infections of opportunistic pathogens, including Strongyloides. We sought to determine the clinical symptoms and demographic characteristics of SARS‐CoV‐2–Strongyloides co‐infection, particularly in patients with severe disease and being treated with immunosuppressive drugs. To do this, we undertook a systematic review of the literature, and searched public accessible scientific databases—the Web of Science, Scopus, PubMed/Medline and Embase –for eligible studies (1 December 2019 to 30 August 2022). The review protocol is registered in PROSPERO (CRD42022377062). Descriptive statistical analyses were used to present the clinical and laboratory parameters of the co‐infection; for this, we calculated prevalence using the following formula: positive cases/total number of cases × 100. Of a total of 593 studies identified, 17 studies reporting 26 co‐infected patients met the criteria for inclusion in this review. The median age of these patients was 55.14 years. Most of cases (53.8%) were treated with dexamethasone, followed by methylprednisolone (26.9%). Eighteen of 26 patients were immigrants living in European countries or the USA; most of these immigrants originated from Latin America (58%) and South‐East Asia (11%). The commonest symptoms of co‐infection were abdominal pain (50%), fever (46.1%), dyspnoea (30.7%) and cough (30.7%), and frequently reported laboratory findings were high absolute eosinophil count (38.4%), high white blood cell count (30.7%), high C‐reactive protein (23.0%) and high neutrophil count (19.2%). Two of the 26 patients (7.7%) had fatal outcomes. Most of the SARS‐CoV‐2–Strongyloides coinfected cases were immigrants living in developed countries, emphasising the need for clinicians in these countries to be aware of clinical and laboratory parameters associated with such co‐infections, as well as the key importance of rapid and accurate diagnostic tests for timely and effective diagnosis and patient management.

show abstract

Section: Discussionmentioning

confidence: 99%

“…This systematic review aimed to inform clinicians about the likely risks, clinical profile and impact of S. stercoralis infection in patients with COVID-19, particularly those with severe disease receiving immunosuppressive drugs. Numerous studies have reviewed the relationship between COVID-19 and viral, fungal and bacterial coinfection(s) [51][52]…”

mentioning

confidence: 99%

Strongyloides coinfection in COVID‐19 patients treated with corticosteroids: A systematic review

Zulfiqar

Gasser

Ghodsian

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…and Aspergillus spp. ; the most common bacterial pathogens are coagulase-negative staphylococci, Klebsiella pneumoniae , Enterococcus spp., Staphylococcus aureus , and Escherichia coli ; and the most common viral pathogens are influenza and the respiratory syncytial virus [ 14 , 15 ]. These infections occur in both developed and developing countries and account for 7% and 10% of all infections, respectively [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

The Dark Side of Nosocomial Infections in Critically Ill COVID-19 Patients

Biondo,

Ponzo,

Midiri

et al. 2023

Life

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a potentially serious acute respiratory infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Since the World Health Organization (WHO) declared COVID-19 a global pandemic, the virus has spread to more than 200 countries with more than 500 million cases and more than 6 million deaths reported globally. It has long been known that viral respiratory tract infections predispose patients to bacterial infections and that these co-infections often have an unfavourable clinical outcome. Moreover, nosocomial infections, also known as healthcare-associated infections (HAIs), are those infections that are absent at the time of admission and acquired after hospitalization. However, the impact of coinfections or secondary infections on the progression of COVID-19 disease and its lethal outcome is still debated. The aim of this review was to assess the literature on the incidence of bacterial co-infections and superinfections in patients with COVID-19. The review also highlights the importance of the rational use of antibiotics in patients with COVID-19 and the need to implement antimicrobial stewardship principles to prevent the transmission of drug-resistant organisms in healthcare settings. Finally, alternative antimicrobial agents to counter the emergence of multidrug-resistant bacteria causing healthcare-associated infections in COVID-19 patients will also be discussed.

show abstract

Bacterial and fungal co-infection is a major barrier in COVID-19 patients: A specific management and therapeutic strategy is required

Cited by 2 publications

References 19 publications

Strongyloides coinfection in COVID‐19 patients treated with corticosteroids: A systematic review

Strongyloides coinfection in COVID‐19 patients treated with corticosteroids: A systematic review

The Dark Side of Nosocomial Infections in Critically Ill COVID-19 Patients

Contact Info

Product

Resources

About